EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Perceptions of Buprenorphine With Naloxone Treatment and the Fear of Precipitated Withdrawal: A Qualitative Exploration With HIV Prevention Trials Network 094 INTEGRA Participants and Staff

Rose A Schmidt iD, Amaya Perez-Brumer, Peter Davidson, Steve Shoptaw, Nabila El-Bassel, Philip Andrew, Jayla Harris, Omar Nieto, Sydney Bornstein, Rashaunna Redd, Jessica Yeager, David Goodman-Meza und 6 weitere

Drug and Alcohol Review · 2026-07 · 45 (5)

DOI: 10.1111/dar.70198 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug and Alcohol Review, online erschienen am 20.06.2026. Verfasst von Rose A Schmidt und 17 weiteren Autor:innen. Beteiligte Einrichtung: Dalla Lana School of Public Health, University of Toronto, Toronto, Canada. Hauptthemen laut MEDLINE: Buprenorphine, Naloxone Drug Combination, Opioid-Related Disorders, HIV Infections, Fear. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, NIAID NIH HHS, NIMH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Uptake of evidence‐based medication for opioid use disorder (MOUD), including buprenorphine–naloxone, remains low despite the expanding US opioid crisis. This study examined participants' and staff perceptions of adopting and delivering buprenorphine–naloxone on a mobile unit providing integrated MOUD and HIV services for people with opioid use disorder who inject drugs in the HPTN 094 INTEGRA trial.

Methods

We conducted semi‐structured interviews with people with opioid use disorder who inject drugs in the intervention or control arm ( n = 77) and mobile unit staff ( n = 38) of HPTN 094 as part of an embedded qualitative implementation science evaluation across five US cities: Houston, Los Angeles, New York City, Philadelphia and Washington, DC. Interviews were transcribed and analysed using a pragmatic inductive and deductive thematic approach.

Results

Fear of precipitated withdrawal was a primary factor shaping perceptions of buprenorphine and other MOUD formulations. This fear was heightened by the widespread presence of fentanyl in the unregulated drug supply. Participants' MOUD preferences were influenced by their treatment goals and by misperceptions of the role of naloxone in buprenorphine and the risk of precipitated withdrawal. Additional barriers included stigma towards MOUD and infrastructure constraints that complicated buprenorphine–naloxone inductions on a mobile unit. Discussion and Conclusions Even with facilitated access, perceptions of evidence‐based MOUD were strongly shaped by fear of precipitated withdrawal. Aligning MOUD formulations with the treatment goals of people who inject drugs, along with expanding flexibility in MOUD access, delivery and induction practices across formulations, may improve uptake of these life‐saving treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Buprenorphine, Naloxone Drug CombinationOpioid-Related DisordersHIV InfectionsFearSubstance Withdrawal SyndromeBuprenorphineHumansFemaleMaleAdultNarcotic AntagonistsQualitative ResearchMiddle AgedOpiate Substitution TreatmentSubstance Abuse, IntravenousNaloxoneMobile Health UnitsUnited StatesAttitude of Health Personnel

Stichwörter der Autor:innen

HIVbuprenorphinemobile health unitsnaloxone drug combinationopiate substitution treatmentopioid‐related disorders

Substanzen

Buprenorphine, Naloxone Drug CombinationNarcotic AntagonistsBuprenorphineNaloxone

Autor:innen und Institutionen

  • Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
  • School of Medicine, University of California San Diego, La Jolla, California, USA.
  • Department of Family Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • School of Social Work, Columbia University, New York, New York, USA.
  • HIV Prevention Trials Network, Durham, North Carolina, USA.
  • Milken Institute School of Public Health, George Washington University, Washington, District of Columbia, USA.

ORCID-Profile: Rose A Schmidt, Cecile Denis, Laramie R Smith

Förderung

  • National Institute of Allergy and Infectious Diseases
  • NIAID NIH HHS
  • NIMH NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • NIH HHS
  • NIDA NIH HHS
  • NIH Office of the Director
  • National Institutes of Health

Zitieren

APA

Schmidt, R. A., Perez-Brumer, A., Davidson, P., Shoptaw, S., El-Bassel, N., Andrew, P., Harris, J., Nieto, O., Bornstein, S., Redd, R., Yeager, J., Goodman-Meza, D., Hasson, A. L., Seigel, M., Denis, C., El-Krab, R., Smith, L. R., & HPTN 094 Team (2026). Perceptions of Buprenorphine With Naloxone Treatment and the Fear of Precipitated Withdrawal: A Qualitative Exploration With HIV Prevention Trials Network 094 INTEGRA Participants and Staff. Drug and Alcohol Review, 45(5). https://doi.org/10.1111/dar.70198

Vancouver

Schmidt RA, Perez-Brumer A, Davidson P, Shoptaw S, El-Bassel N, Andrew P, et al. Perceptions of Buprenorphine With Naloxone Treatment and the Fear of Precipitated Withdrawal: A Qualitative Exploration With HIV Prevention Trials Network 094 INTEGRA Participants and Staff. Drug and Alcohol Review. 2026;45(5). doi:10.1111/dar.70198

BibTeX
@article{Schmidt2026,
  author = {Schmidt, Rose A and Perez-Brumer, Amaya and Davidson, Peter and Shoptaw, Steve and El-Bassel, Nabila and Andrew, Philip and Harris, Jayla and Nieto, Omar and Bornstein, Sydney and Redd, Rashaunna and Yeager, Jessica and Goodman-Meza, David and Hasson, Albert L and Seigel, Marc and Denis, Cecile and El-Krab, Renee and Smith, Laramie R and HPTN 094 Team, HPTN 094 Team},
  title = {Perceptions of Buprenorphine With Naloxone Treatment and the Fear of Precipitated Withdrawal: A Qualitative Exploration With HIV Prevention Trials Network 094 INTEGRA Participants and Staff},
  journal = {Drug and Alcohol Review},
  year = {2026},
  volume = {45},
  number = {5},
  doi = {10.1111/dar.70198}
}
Kostenlos starten →